ProCE Banner Activity

A-BRAVE: Phase III Trial of Adjuvant Avelumab vs Observation in Patients With Early TNBC With Residual Disease Post Neoadjuvant CT or at High Risk After Surgery and Adjuvant CT

Conference Coverage

In the phase III A-BRAVE trial, adjuvant avelumab failed to significantly improve disease-free survival vs observation for patients with early high-risk triple-negative breast cancer but was associated with significant improvement in 3-year overall survival and distant disease–free survival.

Released: June 07, 2024

Expiration: June 06, 2025


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Novartis Pharmaceuticals Corporation.


Daiichi Sankyo, Inc.

Novartis Pharmaceuticals Corporation